undamentalytics Newsletter
Sign in

Aclaris Therapeutics, Inc. income statement

In fiscal 2025, Aclaris Therapeutics, Inc. reported revenue of $7.8m, down 58.2% on the year before, operating income of −$76.4m (a -975.9% margin) and net income of −$64.9m, or −$0.53 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue2646730311988
Cost of revenue1445543322
Gross profit0301226281667
Research and development36616429447898345363
Selling and marketing001———————
General and administrative19262821242532222223
Operating income−54−85−111−51−90−90−97−142−76−86
Income before tax−70−82−114−51−91−87−89−132−65—
Income tax−2——−0——−0———
Net income−69−133−161−51−91−87−88−132−65−76
Diluted EPS−$2.44−$4.03−$3.90−$1.20−$1.60−$1.33−$1.27−$1.71−$0.53−$0.59
Diluted shares (average)28m33m41m43m57m65m70m77m123m129m
EBITDA−54−83−105−50−89−89−96−141−76−86

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ACRS vs COYAACRS vs APLMACRS vs ADAG

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Aclaris Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Aclaris Therapeutics, Inc.